Frontiers of Chemical Science and Engineering

, Volume 8, Issue 3, pp 276–279 | Cite as

Controlled drug delivery systems: the next 30 years

Review Article

Abstract

The drug delivery scientists need to reexamine the advances made during the past 60 years, analyze our current abilities, and design the future technologies that will propel us to achieve the next level of drug delivery technologies. History shows that the first generation (1G) of drug delivery research during 1950–1980 was quite productive, while the second generation (2G) technologies developed during 1980–2010 were not as prolific. The ultimate goal of drug delivery research is to develop clinically useful formulations to treat various diseases. Effective drug delivery systems can be developed by overcoming formulation barriers and/or biological barriers. The engineering approach has a limit in solving the problem, if biological difficulties are not clearly identified and understood. The third generation (3G) drug delivery systems will have to focus on understanding the biological barriers so that they can be overcome by engineering manipulation of the drug delivery systems. Advances in the next 30 years will be most accelerated by starting open dialogues without any preconceived ideas on drug delivery technologies. The new generation of drug delivery scientists needs to be aware of the successes and limitations of the existing technologies to design the new technologies for meaningful advances in the future.

Keywords

drug delivery history formulation barriers nanotechnology clinical product 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lee P I, Li J X. Evolution of oral controlled release dosage forms. In: Wen H, Park K, eds. Oral Controlled Release Formulation Design and Drug Delivery. New Jersey: John Wiley & Sons, Inc., 2010, 21–31CrossRefGoogle Scholar
  2. 2.
    Wen H, Park K. Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice. New York: John Wiley & Sons, 2010, 363CrossRefGoogle Scholar
  3. 3.
    Park K. Facing the truth about nanotechnology in drug delivery. ACS Nano, 2013, 7(9): 7442–7447CrossRefGoogle Scholar
  4. 4.
    Kwon I K, Lee S C, Han B, Park K. Analysis on the current status of targeted drug delivery to tumors. Journal of Controlled Release, 2012, 164(2): 108–114CrossRefGoogle Scholar
  5. 5.
    Hollis C P, Weiss H L, Leggas M, Evers B M, Gemeinhart R A, Li T. Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery. Journal of Controlled Release, 2013, 172(1): 12–21CrossRefGoogle Scholar
  6. 6.
    Stirland D L, Nichols JW, Miura S, Bae Y H. Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. Journal of Controlled Release, 2013, 172(3): 1045–1064CrossRefGoogle Scholar
  7. 7.
    Brabandere L D, Iny A. Thinking in New Boxes: A New Paradigm for Business Creativity. The Boston Consulting Group, 2013Google Scholar

Copyright information

© Higher Education Press and Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Departments of Biomedical Engineering and PharmaceuticsPurdue UniversityWest LafayetteUSA

Personalised recommendations